Samrat Pharmachem Board of Directors

Get the latest insights into the leadership at Samrat Pharmachem. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Lalit Mehta Chairman & Managing Director
Mr. Rajesh Mehta Executive Director & CFO
Mr. Megh Mehta Executive Director
Mr. Mahendra Pipalia Ind. Non-Executive Director
Mr. Samir Kothary Ind. Non-Executive Director
Ms. Renu Dharod Ind. Non-Executive Director

Samrat Pharmachem Share price

SAMRATPH

317.95

2.35 (0.74%)
Last updated on 4 Sep, 2025 | 15:29 IST
BUYSELL
Today's High

325.50

Today's Low

315.60

52 Week Low

302.05

52 Week High

646.00

The current prices are delayed, login to your account for live prices

Samrat Pharmachem FAQs

The board at Samrat Pharmachem consists of experienced professionals, including Mr. Lalit Mehta , Mr. Rajesh Mehta , and others, overseeing the company’s strategic and corporate governance.

Directors at Samrat Pharmachem are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Lalit Mehta is the current chairman at Samrat Pharmachem.

Executive directors at Samrat Pharmachem are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Samrat Pharmachem adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Samrat Pharmachem, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.